Riskpilot← Back to searchSign inGet full accessBo Sjögren Urologi AB
ABActiveOrg 5569817488Knektgatan 1 CMedical specialists activities · NACE 8622Est. 20140 employees
Revenue 2025
SEK 0
EBITDA margin
—
+24% vs 2024
Equity ratio
17.0%
Financial strength
Net profit 2025
SEK 0
-100% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -102K | +24% |
| Net profit | SEK 0 | -100% |
| Total assets | SEK 849K | -66% |
| Equity | SEK 144K | -91% |
| Employees | 0 | — |
Legal name
Bo Sjögren Urologi AB
Org number
5569817488
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
4 september 2014
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva sjukvård i öppen och sluten vård, utbildning och handledning inom vårdsektorn, kapitalförvaltning samt därmed förenlig verksamhet.
Address
Knektgatan 1 C
Email
bo.sjogren@specialistmottagningen.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 5 540 | 5 646 | 2 946 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 955 | 1 202 | 1 546 | −134 | −102 |
| Depreciation & amort. | −110 | −92 | −0 | −0 | −0 |
| EBIT | 845 | 1 110 | 1 546 | −134 | −102 |
| Net financials | −13 | 2 | −9 | −3 | −10 |
| Profit before tax | 623 | 841 | 1 616 | 98 | 5 |
| Tax | −137 | −175 | −340 | −27 | −5 |
| Net profit | 486 | 666 | 1 276 | 71 | 0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 892 | 3 184 | 3 123 | 2 495 | 849 |
| Equity | 1 430 | 1 497 | 2 073 | 1 544 | 144 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 667 | 623 | 65 | 201 | 72 |
| Total debt | 667 | 623 | 65 | 201 | 72 |
EBITDA margin
-10200000.0%
This company
15.8%
Market median
-64557062% vs market
20212025
Equity ratio
17.0%
This company
38.2%
Market median
-55% vs market
20212025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
4.90×
This company
0.62×
Market median
-690% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-09-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BM Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
KG | Audit | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bo Sjögren Urologi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Magnus Sjögren | Chief Executive Officer | 0 companies |
| Kent Gunnar Lundqvist | Audit | 0 companies |
| Sandra Margareta Brissman Sjögren | Deputy Board Member | 0 companies |